The Moscow Endocrine Plant, located in the Nizhny Novgorod region, developed five import-substituting drugs under the federal target program ‘Pharma-2020’.
“Under the Pharma-2020 program, we developed and registered five import-substituting drugs, including anticonvulsant and antiepileptic drugs in solid and injectable dosage forms,” said Ekaterina Yezhova, the company’s First Deputy General Director. “Moreover, on the recommendation of the Ministry of Health and a number of public funds, we have introduced a line of painkillers and other drugs needed to treat people.”
However, specialists of the Moscow Endocrine Plant are not going to stop there. The company plans to launch production of nine more non-invasive pain medications.